Global Epilepsy Market 2010-2014
出 版 商：Infiniti Research
出版日期：2012/02/08
頁 數：29頁
文件格式：PDF
價 格：
USD 1,500 (Single-User License)
USD 1,800 (Multi-User License)
USD 2,500 (Global-User License)
USD 1,800 (Multi-User License)
USD 2,500 (Global-User License)
TechNavio’s analysts forecast the Global Epilepsy market to reach US$8.1 billion by 2014. One of the key factors contributing to this market growth is increasing usage of second-generation drugs. The Global Epilepsy market has also been witnessing a reduction of prices of anti-epileptic drugs. However, intense competition among manufacturers could pose a challenge to the growth of this market.
TechNavio’s report, the Global Epilepsy Market 2010–2014, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the first-line therapies and the second-line therapies and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and UCB SA.
Key questions answered in this report:
What will the market size be in 2014 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
TechNavio’s report, the Global Epilepsy Market 2010–2014, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the first-line therapies and the second-line therapies and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and UCB SA.
Key questions answered in this report:
What will the market size be in 2014 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
01. Executive Summary
02. Introduction
03. Market Coverage
04. Market Landscape
05. Vendor Landscape
06. Buying Criteria
07. Market Growth Drivers
08. Drivers and their Impact
09. Market Challenges
10. Market Trends
11. Key Vendor Analysis
11.1 Pfizer Inc.
11.2 UCB SA
11.3 GlaxoSmithKline plc.
11.4 Novartis AG
12. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Epilepsy Market 2010–2014 (US$ billions)
Exhibit 2: Global Epilepsy Market by Geographical Segmentation 2010
Exhibit 3: Global Epilepsy Market by Vendor Segmentation 2010
02. Introduction
03. Market Coverage
04. Market Landscape
05. Vendor Landscape
06. Buying Criteria
07. Market Growth Drivers
08. Drivers and their Impact
09. Market Challenges
10. Market Trends
11. Key Vendor Analysis
11.1 Pfizer Inc.
11.2 UCB SA
11.3 GlaxoSmithKline plc.
11.4 Novartis AG
12. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Epilepsy Market 2010–2014 (US$ billions)
Exhibit 2: Global Epilepsy Market by Geographical Segmentation 2010
Exhibit 3: Global Epilepsy Market by Vendor Segmentation 2010
